The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to < 100 × 109/L) at BaselinePaola Guglielmelli, Heinz Gisslinger, Alessandro M. Vannucchi et al.|Blood|2020Cited by 7